Extendicare Inc. (TSE:EXE – Free Report) – Leede Financial increased their FY2024 earnings estimates for shares of Extendicare in a note issued to investors on Wednesday, November 13th. Leede Financial analyst D. Loe now anticipates that the company will post earnings per share of $1.03 for the year, up from their previous estimate of $0.89. The consensus estimate for Extendicare’s current full-year earnings is $0.61 per share. Leede Financial also issued estimates for Extendicare’s FY2027 earnings at $1.49 EPS.
EXE has been the subject of several other reports. Royal Bank of Canada raised their price target on shares of Extendicare from C$8.50 to C$9.50 in a research note on Monday, August 19th. TD Securities raised their price objective on Extendicare from C$9.50 to C$10.50 and gave the company a “hold” rating in a report on Thursday.
Extendicare Trading Up 1.3 %
EXE opened at C$10.14 on Friday. The stock has a market capitalization of C$846.39 million, a P/E ratio of 14.91 and a beta of 1.26. The company has a current ratio of 0.60, a quick ratio of 0.98 and a debt-to-equity ratio of 305.80. Extendicare has a 12 month low of C$6.41 and a 12 month high of C$10.43. The firm’s fifty day simple moving average is C$9.27 and its 200 day simple moving average is C$8.15.
Extendicare Announces Dividend
The company also recently disclosed a monthly dividend, which was paid on Friday, November 15th. Stockholders of record on Thursday, October 31st were given a $0.04 dividend. This represents a $0.48 dividend on an annualized basis and a dividend yield of 4.73%. The ex-dividend date was Thursday, October 31st. Extendicare’s dividend payout ratio (DPR) is presently 70.59%.
Extendicare Company Profile
Extendicare Inc, through its subsidiaries, provides care and services for seniors in Canada. The company offers long term care (LTC) services; and home health care services, such as nursing care, occupational, physical and speech therapy, and assistance with daily activities, as well as management, consulting, and other services to third parties.
Recommended Stories
- Five stocks we like better than Extendicare
- Why Are Stock Sectors Important to Successful Investing?
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- How to Invest in Biotech Stocks
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Time to Load Up on Home Builders?
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.